We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+23.66%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.11B
AUM Growth
+$195M
Cap. Flow
+$57.8M
Cap. Flow %
5.19%
Top 10 Hldgs %
48.19%
Holding
72
New
18
Increased
12
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$49.7M
2
ENDP
Endo International plc
ENDP
+$46.9M
3
ALR
Alere Inc
ALR
+$29.1M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$27.8M
5
BIIB icon
Biogen
BIIB
+$21.5M

Top Sells

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$45.4M
2
CELG
Celgene Corp
CELG
+$38.3M
3
GILD icon
Gilead Sciences
GILD
+$34.7M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$19.4M
5
AZN icon
AstraZeneca
AZN
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.46%
2 Miscellaneous 10.8%
3 Financials 2.03%
4 Technology 1.63%
5 Communication Services 1.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$96.7M 8.69%
13,125,594
+1,267,300
+11% +$9.02M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$66.9M 6%
900,879
+179,247
+25% +$12.7M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$63.5M 5.7%
5,832,228
-1,043,046
-15% -$9.19M
BHC icon
4
Bausch Health
BHC
$2.36B
$53.3M 4.79%
268,519
-69,958
-21% -$12.4M
TEVA icon
5
Teva Pharmaceuticals
TEVA
$42.5B
$53.2M 4.78%
+853,973
New +$49.7M
ENDP
6
DELISTED
Endo International plc
ENDP
$50.3M 4.51%
+560,443
New +$46.9M
ASPX
7
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$41.9M 3.76%
+417,533
New +$27.8M
BIIB icon
8
Biogen
BIIB
$32.3B
$41.3M 3.7%
97,713
+54,600
+127% +$21.5M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$37.2M 3.34%
1,052,666
+68,700
+7% +$2.34M
ALR
10
DELISTED
Alere Inc
ALR
$32.5M 2.92%
+664,138
New +$29.1M
CMRX
11
DELISTED
Chimerix, Inc.
CMRX
$31.8M 2.86%
844,456
-312,728
-27% -$12.4M
INSM icon
12
Insmed
INSM
$25.9B
$28.7M 2.58%
1,381,828
+369,457
+36% +$6.51M
RCPT
13
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$26.3M 2.36%
159,413
-153,323
-49% -$19.4M
LAB icon
14
Standard BioTools
LAB
$252M
$23.7M 2.13%
562,437
-48,005
-8% -$1.9M
AET
15
DELISTED
Aetna Inc
AET
$22.6M 2.03%
+211,974
New +$20.8M
DVA icon
16
DaVita
DVA
$11.5B
$21.6M 1.94%
+265,858
New +$20.4M
TVTY
17
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$21.2M 1.9%
1,074,033
+5,544
+0.5% +$116K
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.52B
$20.7M 1.85%
+332,600
New +$18.5M
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$19.9M 1.79%
1,415,482
+344,487
+32% +$4.69M
CIVI
20
DELISTED
Civitas Solutions, Inc.
CIVI
$18.4M 1.65%
879,485
– –
CSLT
21
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$18.1M 1.63%
2,336,498
+1,089,230
+87% +$9.32M
MODN
22
DELISTED
MODEL N, INC.
MODN
$17.5M 1.57%
1,461,678
– –
JAZZ icon
23
Jazz Pharmaceuticals
JAZZ
$15.9B
$17.3M 1.55%
+100,000
New +$17.2M
ZSPH
24
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$17.1M 1.53%
405,688
-119,014
-23% -$5.44M
ADVM
25
DELISTED
Adverum Biotechnologies
ADVM
$17.1M 1.53%
42,113
-27,794
-40% -$11.7M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2015 Portfolio in Review

As of Q1 2015, Redmile Group held 72 positions worth $1.11B, up 21% from $918M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group deployed $57.8M of net new capital in Q1 2015, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Teva Pharmaceuticals: 853,973 shares worth $53.2M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was RECEPTOS INC COM STK (DE), an estimated $19.4M trimmed.

  • Redmile Group's largest Q1 2015 buy was Teva Pharmaceuticals: 853,973 shares worth $53.2M.
  • Redmile Group added most to Biogen in Q1 2015, an estimated $21.5M increase.
  • Redmile Group's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $19.4M.
  • Redmile Group fully exited Rite Aid Corporation in Q1 2015, selling an estimated $45.4M.
  • Redmile Group's ten largest holdings make up 48% of its $1.11B portfolio in Q1 2015.
  • Redmile Group opened 18 new positions and closed 18 in Q1 2015.
  • Redmile Group's portfolio value rose 21% quarter-over-quarter to $1.11B.

Based on Redmile Group's 13F filing for Q1 2015, filed 18 May 2015.